HER2+ Breast Cancer

David Rimm, MD, PhD, discusses ways that the use of ADCs in breast cancer might adapt to reflect emerging categories of detectable HER2 expression levels.

The top 5 OncLive TV videos of the week cover insights in kidney cancer, myeloproliferative neoplasms, breast cancer, systemic mastocytosis, and pancreatic cancer.

Vikram C. Gorantla, MD, discusses future directions for sequencing available therapies for patients with breast cancer who develop brain metastases.

Vikram C. Gorantla, MD, discusses real-world treatment patterns with T-DXd vs tucatinib-based therapy in HER2-positive breast cancer with brain metastases.

Vikram C. Gorantla, MD, notes real-world treatment patterns and outcomes with second-line T-DXd vs tucatinib-based therapy in HER2-positive breast cancer.

Vikram C. Gorantla, MD, discusses an analysis of T-DXd vs tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer with brain metastases.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in January 2025 spanning tumor types.

PATINA shows palbociclib added to anti-HER2 plus endocrine maintenance prolongs progression-free survival by 15+ months in HR+, HER2+ metastatic breast cancer.

The emergence of ultrasensitive ctDNA and CSF testing may help alter monitoring strategies and adaptive clinical trial designs in metastatic breast cancer.

Sara Tolaney, MD, MPH, discusses the recent FDA approval of T-DXd and pertuzumab for HER2-positive breast cancer and its supporting data.

The EMA has validated a Type II variation application for trastuzumab deruxtecan plus pertuzumab in first-line HER2-positive metastatic breast cancer.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, breast cancer, and colorectal cancer.

The FDA cleared narsoplimab for TA-TMA, an NDA seeking approval of bezuclastinib in nonadvanced systemic mastocytosis has been submitted, and more.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in December 2025 spanning tumor types.

The FDA approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma and granted a pair of breakthrough therapy designations.

Post-neoadjuvant T-DXd has received breakthrough therapy designation from the FDA for HER2-positive early breast cancer with residual invasive disease.

The FDA approved T-DXd plus pertuzumab in HER2+ breast cancer, subcutaneous amivantamab in EGFR+ NSCLC, and rucaparib in BRCA-mutated mCRPC.

Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.

The FDA has expanded the indications of 2 assays to identify patients with HER2+ breast cancer for treatment with T-DXd.

The FDA approved T-DXd plus pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast cancer.

T-DXd yielded iDFS improvements in HER2-positive early breast cancer with residual invasive disease, irrespective of HER2 expression of neoadjuvant chemotherapy type.

Tucatinib plus HP improved median investigator-assessed PFS by 8.6 months as first-line maintenance vs HP alone in HER2-positive metastatic breast cancer.

Frontline treatment with T-DXd plus pertuzumab improved QOL vs THP in patients with HER2-positive advanced or metastatic breast cancer.

Leading experts highlight key HER2-positive studies ahead of SABCS 2025.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.